-
Je něco špatně v tomto záznamu ?
Erythropoietin administration increases splenic erythroferrone protein content and liver TMPRSS6 protein content in rats
I. Gurieva, J. Frýdlová, Z. Rychtarčíková, M. Vokurka, J. Truksa, J. Krijt,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- erythropoetin farmakologie MeSH
- játra metabolismus MeSH
- krysa rodu rattus MeSH
- peptidové hormony metabolismus MeSH
- potkani Wistar MeSH
- serinové endopeptidasy metabolismus MeSH
- slezina metabolismus MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Erythroferrone (ERFE) and TMPRSS6 are important proteins in the regulation of iron metabolism. The objective of the study was to examine splenic ERFE and liver TMPRSS6 synthesis in rats treated with a combination of iron and erythropoietin (EPO). EPO was administered to female Wistar rats at 600U/day for four days, iron-pretreated rats received 150mg of iron before EPO treatment. Content of ERFE and TMPRSS6 proteins was determined by commercial antibodies. Iron pretreatment prevented the EPO-induced decrease in hepcidin expression. Content of phosphorylated SMAD 1,5,8 proteins was decreased in the liver by both EPO and iron plus EPO treatment. Fam132b expression in the spleen was increased both by EPO and iron plus EPO treatments; these treatments also significantly induced splenic Fam132a expression. ERFE protein content in the spleen was increased both by EPO and iron plus EPO to a similar extent. EPO administration increased TMPRSS6 content in the plasma membrane-enriched fraction of liver homogenate; in iron-pretreated rats, this increase was abolished. The results confirm that iron pretreatment prevents the EPO-induced decrease in liver Hamp expression. This effect probably occurs despite high circulating ERFE levels, since EPO-induced ERFE protein synthesis is not influenced by iron pretreatment.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033982
- 003
- CZ-PrNML
- 005
- 20181017150439.0
- 007
- ta
- 008
- 181008s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bcmd.2017.02.007 $2 doi
- 035 __
- $a (PubMed)28282554
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Gurieva, Iuliia $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 10
- $a Erythropoietin administration increases splenic erythroferrone protein content and liver TMPRSS6 protein content in rats / $c I. Gurieva, J. Frýdlová, Z. Rychtarčíková, M. Vokurka, J. Truksa, J. Krijt,
- 520 9_
- $a Erythroferrone (ERFE) and TMPRSS6 are important proteins in the regulation of iron metabolism. The objective of the study was to examine splenic ERFE and liver TMPRSS6 synthesis in rats treated with a combination of iron and erythropoietin (EPO). EPO was administered to female Wistar rats at 600U/day for four days, iron-pretreated rats received 150mg of iron before EPO treatment. Content of ERFE and TMPRSS6 proteins was determined by commercial antibodies. Iron pretreatment prevented the EPO-induced decrease in hepcidin expression. Content of phosphorylated SMAD 1,5,8 proteins was decreased in the liver by both EPO and iron plus EPO treatment. Fam132b expression in the spleen was increased both by EPO and iron plus EPO treatments; these treatments also significantly induced splenic Fam132a expression. ERFE protein content in the spleen was increased both by EPO and iron plus EPO to a similar extent. EPO administration increased TMPRSS6 content in the plasma membrane-enriched fraction of liver homogenate; in iron-pretreated rats, this increase was abolished. The results confirm that iron pretreatment prevents the EPO-induced decrease in liver Hamp expression. This effect probably occurs despite high circulating ERFE levels, since EPO-induced ERFE protein synthesis is not influenced by iron pretreatment.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a erythropoetin $x farmakologie $7 D004921
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a játra $x metabolismus $7 D008099
- 650 _2
- $a peptidové hormony $x metabolismus $7 D036361
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a serinové endopeptidasy $x metabolismus $7 D012697
- 650 _2
- $a slezina $x metabolismus $7 D013154
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Frýdlová, Jana $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Rychtarčíková, Zuzana $u Institute of Biotechnology, BIOCEV Research Center, Czech Academy of Sciences, Prague, Czech Republic.
- 700 1_
- $a Vokurka, Martin $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Truksa, Jaroslav $u Institute of Biotechnology, BIOCEV Research Center, Czech Academy of Sciences, Prague, Czech Republic.
- 700 1_
- $a Krijt, Jan $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: jkri@lf1.cuni.cz.
- 773 0_
- $w MED00005053 $t Blood cells, molecules & diseases $x 1096-0961 $g Roč. 64, č. - (2017), s. 1-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28282554 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181017150938 $b ABA008
- 999 __
- $a ok $b bmc $g 1339676 $s 1030976
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 64 $c - $d 1-7 $e 20170228 $i 1096-0961 $m Blood cells, molecules, & diseases $n Blood Cells Mol Dis $x MED00005053
- LZP __
- $a Pubmed-20181008
